Heron Therapeutics (NASDAQ: HRTX) reported Q2 EPS of ($0.35), $0.13 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $31.76 million versus the consensus estimate of $31.7 million.

Reiterating full-year net product sales guidance for the oncology care franchise of $99-$103 million

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.